A review of new science, in plain language

Proceedings of the National Academy of Sciences  ·  13 November 2026  ·  From issue 67

Selectively disrupting lysine acetyltransferase p300 and ZEB1 interaction prevents tumor progression while enhancing antitumor immunity

In mice, a new drug blocked a cancer protein's stabilizer and shrank tumors.

Jing-Yu Luo, Bo-Xue Ren et al.

A helper protein tags a cancer-driving protein called ZEB1 with a small chemical mark, making ZEB1 more stable. This helps tumors hide from the immune system and grow faster. In mice, a new drug called WY6 blocked this process, shrank tumors, and worked even better alongside existing immune therapy drugs.

Integrity screen: passed (3 checks) Checked 15 November 2026. Read the source

The plain-language reading of this paper is in the full issue, for subscribers.

Read the full issue

Five vetted papers in plain language, free, every two days

Five papers free every issue, about 15 emails a month. No spam. Leave in one click.

Also in issue 67 15 papers
More from Proceedings of the National Academy of Sciences